Natriumjodid [123i] Ge Healthcare (Sodium Iodide (123 I))

Sodium Iodide (I-123), the active ingredient in Natriumjodid [123i] Ge Healthcare, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is used for diagnostic imaging of thyroid function and morphology in patients requiring thyroid scintigraphy, evaluation of nodules, or detection of metastatic disease.

GNH USA supplies Natriumjodid [123i] Ge Healthcare as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Natriumjodid [123i] Ge Healthcare is a radiopharmaceutical that targets thyroid tissue for diagnostic imaging. - Thyroid scintigraphy: enables visualization of thyroid uptake to assess function and anatomy. - Evaluation of thyroid nodules: helps differentiate benign from malignant nodules based on iodine uptake patterns. - Detection of metastatic thyroid cancer: identifies iodine‑avid metastatic lesions throughout the body.

Adverse reactions are generally infrequent but may occur after administration of the radiopharmaceutical.

Common Side Effects: - Nausea: mild and transient. - Headache: mild discomfort shortly after injection. - Warmth or flushing at the injection site. - Transient metallic taste.

Serious or Rare Side Effects: - Allergic reaction: rash, urticaria, or anaphylaxis. - Hypersensitivity: bronchospasm or angioedema. - Radiation‑induced thyroiditis: inflammation of thyroid tissue presenting with pain or swelling. - Severe hypotension: rare but possible during rapid injection. - Hematologic changes: transient leukopenia or thrombocytopenia in very high exposures.

Prior to use, several safety considerations should be observed. - Pregnancy: unknown risk; avoid unless essential for diagnosis. - Breastfeeding: unknown safety; consider alternative imaging. - Thyroid function: assess baseline function to interpret results accurately. - Radiation safety: follow ALARA principles and protect staff and family members. - Renal impairment: monitor because excretion may be delayed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium Iodide I-123 may interact with other agents that affect iodine handling or thyroid imaging.

Major Interactions (Avoid): - Iodine‑containing contrast agents: can block thyroid uptake and compromise imaging. - Antithyroid drugs (methimazole, propylthiouracil): reduce tracer accumulation. - Lithium: alters iodine transport and may affect image quality.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement therapy: may influence interpretation of uptake patterns. - Amiodarone: high iodine load can interfere with tracer distribution. - Diuretics: may affect renal clearance of the radiotracer.